尼达尼布联合吡非尼酮治疗特发性肺纤维化:INJOURNEY 试验
INJOURNEY 是一项开放标签随机试验,在完成 4–5 周尼达尼布 150 mg 每日两次导入期、且筛选时 FVC 大于或等于预测值 50% 的 IPF 患者中,比较尼达尼布联合吡非尼酮与尼达尼布单药治疗 12 周的安全性与探索性疗效。主要终点为基线至第 12 周治疗期间胃肠道不良事件发生率,联合组为 69.8%(37/53),单药组为 52.9%(27/51)。联合治疗安全性可控,支持进一步研究 IPF 联合方案。
要点
- 联合组治疗期间胃肠道不良事件发生率为 69.8%(37/53),单药组为 52.9%(27/51)。
- 尼达尼布单用与联用吡非尼酮时,其血浆谷浓度相似。
- 第 12 周 FVC 较基线平均变化:联合组 -13.3(17.4)ml,单药组 -40.9(31.4)ml,属探索性结果。
核心结论
- 尼达尼布联合吡非尼酮在 IPF 患者中安全性可控、耐受性可管理,与该药各自的不良事件特征一致。
- 这些数据支持进一步研究 IPF 的联合治疗方案。
研究设计与样本
- 开放标签随机试验,患者为筛选时 FVC 大于或等于预测值 50% 的 IPF 患者。
- 患者先接受 4–5 周尼达尼布 150 mg 每日两次导入期,未减量或中断治疗者进入随机分组。
- 随机接受尼达尼布 150 mg 每日两次联合吡非尼酮(滴定至 801 mg 每日三次)或尼达尼布 150 mg 每日两次单药治疗,疗程 12 周。
- 主要终点为基线至第 12 周治疗期间胃肠道不良事件发生率,分析为描述性和探索性。
- 试验注册号 NCT02579603。
主要发现
- 治疗期间胃肠道不良事件:联合组 37/53(69.8%),单药组 27/51(52.9%)。
- 尼达尼布单用或联用吡非尼酮时,其给药前血浆谷浓度相似。
- 第 12 周 FVC 较基线平均(SE)变化:联合组(n=48)-13.3(17.4)ml,单药组(n=44)-40.9(31.4)ml。
临床怎么用
- 对完成尼达尼布导入期且耐受良好的 IPF 患者,可考虑加用吡非尼酮并密切监测胃肠道不良事件。
- 联用吡非尼酮未见尼达尼布谷浓度明显改变,但仍需关注两药各自的不良事件谱。
局限性
- 开放标签设计,未设盲。
- 样本量小,疗效分析为描述性和探索性。
- 随访仅 12 周,长期安全性与疗效未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis (IPF), but the disease continues to progress. More data are needed on the safety and efficacy of combination therapy with nintedanib and add-on pirfenidone. OBJECTIVES: To investigate safety, tolerability, and pharmacokinetic and exploratory efficacy endpoints in patients treated with nintedanib and add-on pirfenidone versus nintedanib alone. METHODS: Patients with IPF and FVC greater than or equal to 50% predicted at screening who completed a 4- to 5-week run-in with nintedanib 150 mg twice daily without dose reduction or treatment interruption were randomized to receive nintedanib 150 mg twice daily with add-on pirfenidone (titrated to 801 mg three times daily) or nintedanib 150 mg twice daily alone in an open-label manner for 12 weeks. The primary endpoint was the percentage of patients with on-treatment gastrointestinal adverse events from baseline to Week 12. Analyses were descriptive and exploratory. MEASUREMENTS AND MAIN RESULTS: On-treatment gastrointestinal adverse events were reported in 37 of 53 patients (69.8%) treated with nintedanib with add-on pirfenidone and 27 of 51 patients (52.9%) treated with nintedanib alone. Predose plasma trough concentrations of nintedanib were similar when it was administered alone or with add-on pirfenidone. Mean (SE) changes from baseline in FVC at Week 12 were -13.3 (17.4) ml and -40.9 (31.4) ml in patients treated with nintedanib with add-on pirfenidone (n = 48) and nintedanib alone (n = 44), respectively. CONCLUSIONS: Nintedanib with add-on pirfenidone had a manageable safety and tolerability profile in patients with IPF, in line with the adverse event profiles of each drug. These data support further research into combination regimens in the treatment of IPF. Clinical trial registered with www.clinicaltrials.gov (NCT02579603).
引用
- Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2018. PMID: 28889759. doi:10.1164/rccm.201706-1301OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。